publication venue for Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.. :-. 2016 Long-term risk of medical conditions associated with breast cancer treatment.. 145:233-243. 2014 TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.. 132:781-791. 2012 The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.. 132:355-363. 2012 Three-dimensional collagen represses cyclin E1 via ?1 integrin in invasive breast cancer cells.. 127:397-406. 2011 GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.. 123:51-58. 2010 Genomic instability demonstrates similarity between DCIS and invasive carcinomas.. 117:17-24. 2009 Mammary field cancerization: molecular evidence and clinical importance.. 118:229-239. 2009 SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.. 130:123-131. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.. 129:107-116.
